Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Dexrazoxano cloridrato nella prevenzione degli effetti collaterali cardiaci della chemioterapia nei partecipanti con tumori del sangue

6 novembre 2026 aggiornato da: M.D. Anderson Cancer Center

Cardioprotezione con dexrazoxano nella leucemia mieloide acuta (LMA), nella sindrome mielodisplastica ad alto rischio (MDS), nella fase blastica mieloide della leucemia mieloide cronica (LMC), nella LMA Ph+ e nella fase blastica mieloide delle neoplasie mieloproliferative

This phase II trial studies how well dexrazoxane hydrochloride works in preventing heart-related side effects of chemotherapy in participants with blood cancers, such as acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, and myeloproliferative neoplasms. Chemoprotective drugs, such as dexrazoxane hydrochloride, may protect the heart from the side effects of drugs used in chemotherapy, such as cladribine, idarubicin, cytarabine, and gemtuzumab ozogamicin, in participants with blood cancers.

Panoramica dello studio

Descrizione dettagliata

PRIMARY OBJECTIVES:

I. To estimate the percentage of patients experiencing a decrease in left ventricular ejection fraction (LVEF) of 10 percent from baseline or decrease in LVEF below the normal limit of 50% during treatment with dexrazoxane (dexrazoxane hydrochloride) combined with cladribine, idarubicin, cytarabine, and Mylotarg (gemtuzumab ozogamicin) within the first 6-months of treatment.

SECONDARY OBJECTIVES:

I. To estimate the incidence of these cardiac symptoms while on dexrazoxane combined with idarubicin-based treatment: clinical heart failure, exertional dyspnea, orthopnea, S3 gallop, acute coronary syndrome, acute pulmonary edema and life-threatening arrhythmias.

II. To assess and monitor the change of troponin I (while still standard of care at MD Anderson) and high-sensitivity troponin T during treatment.

III. Collect safety/toxicity profile. IV. To assess rates of complete remission (CR)/complete remission with incomplete blood count recovery (CRi). (Cohorts 1-3) V. Other efficacy endpoints of interest include overall response, overall survival, event-free survival and remission duration. (Cohorts 1-3) VI. To assess the recurrence-free survival rate at 6 months. (Cohort 4)

EXPLORATORY OBJECTIVES:

I. To assess the metal chelation effects of dexrazoxane combined with chemotherapy (Mylotarg, cladribine, idarubicin, and cytarabine) by quantifying concentrations of toxic and essential metals and isotopic abundance ratios of blood and bone marrow before and during treatment.

II. To study and describe the relationship between pretreatment patient / disease characteristics (including cytogenetic and molecular abnormalities) and clinical outcomes.

III. To identify molecular biomarkers predictive of response to therapy. IV. To study and describe the relationship between patient / disease characteristics, use of intrathecal prophylaxis, and incidence of leptomeningeal disease.

V. To observe rates of fungal and other infections on the regimen. VI. To study environmental exposure data based on an environmental health assessment survey.

VII. To explore the impact of minimal residual disease (MRD) on relapse.

OUTLINE:

INDUCTION PHASE: Participants receive gemtuzumab ozogamicin intravenously (IV) over 2 hours on days 1, 4, and 7, cladribine IV over 1-2 hours on days 1-5, dexrazoxane hydrochloride IV over 15 minutes on days 1-3, idarubicin IV over 30 minutes on days 1-3, and cytarabine IV over 2 hours on days 1-5. Treatment repeats every 3-7 weeks for up to 2 courses in the absence of disease progression or unacceptable toxicity.

CONSOLIDATION PHASE: After induction phase, participants receive gemtuzumab ozogamicin IV over 2 hours on day 1, cladribine IV over 1-2 hours on days 1-3, dexrazoxane hydrochloride IV over 15 minutes on days 1-2, idarubicin IV over 30 minutes on days 1-2, and cytarabine IV over 2 hours on days 1-3. Treatment repeats every 3-7 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

MAINTENANCE PHASE: Participants who go into remission or who are already in remission receive gemtuzumab ozogamicin IV over 2 hours on day 1 of course 1 and then every 2-3 months as needed. Participants also receive dexrazoxane hydrochloride IV over 15 minutes and idarubicin IV over 30 minutes on day 1, and cytarabine subcutaneously (SC) on days 1-7. Courses repeat every 3-7 weeks for 32 months in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, participants are followed up every 6-12 months.

Tipo di studio

Interventistico

Iscrizione (Stimato)

100

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Texas
      • Houston, Texas, Stati Uniti, 77030
        • Reclutamento
        • M D Anderson Cancer Center
        • Investigatore principale:
          • Maro Ohanian
        • Contatto:
          • Maro Ohanian
          • Numero di telefono: 713-792-2631

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

12 anni e precedenti (Bambino, Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Baseline left ventricular ejection fraction (LVEF) is greater than or equal to 50% by echocardiography (echo) or multigated acquisition (MUGA) scan.
  • Patients of child bearing potential should use contraception.
  • Patients with a diagnosis of acute myeloid leukemia (AML), or high risk myelodysplastic syndrome (MDS) (>= 10% blasts or International Prognostic Scoring System [IPSS] >= intermediate-2) or high-risk myeloproliferative neoplasm will be eligible.
  • Patients with untreated or previously untreated chronic myeloid leukemia (CML) in myeloid blast phase or (Philadelphia chromosome-positive (Ph+) AML are also eligible.
  • Patients with myeloproliferative neoplasms in blast phase will be eligible.
  • Patients with isolated extramedullary myeloid neoplasm will be eligible.
  • Patients with active CNS (central nervous system) disease are eligible.
  • Bilirubin < 2mg/dL.
  • AST (aspartate aminotransferase) and/or ALT (alanine aminotransferase) < 3 x ULN (upper limit of normal) - or < 5 x ULN if related to leukemic involvement.
  • Creatinine < 1.5 x ULN.
  • Hyperbilirubinemia is allowed if due to Gilbert's hyperbilirubinemia.
  • A negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial.
  • Women of childbearing potential and men must agree to use contraception prior to study entry and for the duration of study participation.
  • Patient must have the ability to understand the requirements of the study and signed informed consent. A signed informed consent by the patient or his legally authorized representative is required prior to their enrollment on the protocol.
  • Prior therapy for any of the cohorts may include with hydroxyurea, rescue doses of cytarabine, various combination-chemotherapy regimens, hematopoietic growth factors, azacytidine, decitabine, ATRA (all-trans retinoic acid).
  • Cohort 1: Frontline cohort patients are eligible in the frontline cohort if they are untreated or previously treated already in CR if they received 3 or fewer cycles of previous chemotherapy (including either 1 induction and 2 consolidations or 2 inductions and 1 consolidation).
  • Cohort 2: Salvage cohort in 1st and 2nd salvage patients are eligible in the salvage cohort 2 if they have active disease after first or second relapse or if they are in CR after previously documented first or second relapse as long as they if they have received 3 or fewer cycles of chemotherapy to achieve the most current CR.
  • Cohort 3: Salvage cohort in 3rd salvage and beyond patients may be eligible in salvage cohort 3 if they have active disease after 3rd or greater relapse or if they are in CR after a previously documented relapse (3rd or greater), but may have only received 3 or fewer cycles of chemotherapy to achieve the most current CR.
  • Cohort 4: Maintenance cohort: Patients in CR who are considered by treating physician to benefit from maintenance therapy are eligible for maintenance therapy with dexrazoxane combined with idarubicin plus cytarabine.

Exclusion Criteria:

  • Any condition, including the presence of laboratory abnormalities, which judged by the investigator, places the patient at unacceptable risk.
  • Active heart disease defined as: Unstable coronary syndromes, unstable or severe angina, recent myocardial infarction (MI) within 6 months.
  • Decompensated heart failure (HF).
  • Clinically significant arrhythmias.
  • Severe valvular disease.
  • History of coronary artery disease (CAD).
  • Pregnant women are excluded from this study because the agents used in this study have the potential for teratogenic or abortifacient effects. Because there is a potential risk for adverse events in nursing infants secondary to treatment of the mother with the chemotherapy agents, breastfeeding should also be avoided.
  • Psychiatric illness/social situations that would limit compliance with study requirements per the judgment of the investigator.
  • Patient with documented hypersensitivity to any of the components of the chemotherapy program.
  • Men and women of childbearing potential who do not practice contraception.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Terapia di supporto
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Supportive care (dexrazoxane hydrochloride, chemotherapy)

See detailed description.

Given IV

Altri nomi:
  • .beta.-Citosina arabinoside
  • 1-.beta.-D-Arabinofuranosil-4-ammino-2(1H)pirimidinone
  • 1-.beta.-D-Arabinofuranosilcitosina
  • 1-Beta-D-arabinofuranosil-4-ammino-2(1H)pirimidinone
  • 1-Beta-D-arabinofuranosilcitosina
  • 1.beta.-D-Arabinofuranosilcitosina
  • 2(1H)-pirimidinone, 4-ammino-1-beta-D-arabinofuranosil-
  • 2(1H)-pirimidinone, 4-ammino-1.beta.-D-arabinofuranosil-
  • Alessandro
  • Ara-C
  • Cellula ARA
  • Arabo
  • Arabinofuranosilcitosina
  • Arabinosilcitosina
  • Aracitidina
  • Aracitina
  • CHX-3311
  • Citarabinum
  • Cytarbel
  • Cytosar
  • Citosina Arabinoside
  • Citosina-.beta.-arabinoside
  • Citosina-beta-arabinoside
  • Erpalfa
  • Starasid
  • Tarabina PFS
  • U19920
  • U-19920
  • Udicil
  • WR-28453
  • Beta-citosina Arabinoside

Given IV

Altri nomi:
  • Mylotarg
  • Anticorpo monoclonale anti-CD33 umanizzato coniugato con calicheamicina
  • CDP-771
  • CMA-676
  • gemtuzumab
  • hP67.6-Calicheamicina
  • WAY-CMA-676

Given IV

Altri nomi:
  • 4-Demetossidaunomicina
  • 4-demetossidaunorubicina
  • 4-DMDR

Given IV

Altri nomi:
  • 2-CdA
  • CDA
  • 2 CDA
  • Cladribina
  • Leustat
  • Leustatina
  • RWJ-26251

Given IV

Altri nomi:
  • Cardiossano
  • Totetto
  • Zinecard

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of patients experiencing a decrease in left ventricular ejection fraction (LVEF)
Lasso di tempo: Baseline up to 6 months

Will assess a decrease in LVEF of 10 percent from baseline or decrease in LVEF below the normal limit of 50% during treatment with dexrazoxane hydrochloride combined with cladribine, idarubicin, cytarabine, and gemtuzumab ozogamicin.

Baseline up to 6 months

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Incidenza di eventi avversi
Lasso di tempo: Fino a 1 anno
Fino a 1 anno
Tassi di remissione completa (CR)/remissione completa con recupero incompleto dell'emocromo (CRi) (Coorti 1-3)
Lasso di tempo: Fino a 1 anno
Fino a 1 anno
Risposta complessiva (Coorti 1-3)
Lasso di tempo: Fino a 1 anno
Fino a 1 anno
Sopravvivenza globale (coorti 1-3)
Lasso di tempo: Fino a 1 anno
Fino a 1 anno
Sopravvivenza libera da eventi (Coorti 1-3)
Lasso di tempo: Fino a 1 anno
Fino a 1 anno
Durata della remissione (coorti 1-3)
Lasso di tempo: Fino a 1 anno
Fino a 1 anno
Incidence of cardiac symptoms
Lasso di tempo: Up to 1 year

Cardiac symptoms to be evaluated include: clinical heart failure, exertional dyspnea, orthopnea, S3 gallop, acute coronary syndrome, acute pulmonary edema and life-threatening arrhythmias

Up to 1 year
Assessment of change in troponin I and high-sensitivity troponin T
Lasso di tempo: Up to 1 year

Troponin levels will be collected before and after the day 1 dose of idarubicin each month during induction, consolidation, and maintenance therapy.

Up to 1 year
Recurrence-free survival
Lasso di tempo: Up to 6 months

The recurrence-free survival rate at 6 months will be a binary endpoint where the recurrence including death occurred within 6 months of treatment will be considered as "recurrence event".

Up to 6 months

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Assessment of metal chelation effects of dexrazoxane and chemotherapy
Lasso di tempo: Up to 1 year

Metal chelation effects assessed by utilizing technologies commonly used in the geochemistry.

Up to 1 year
Assessment of minimal residual disease (MRD)
Lasso di tempo: Up to 1 year

Will explore the impact of MRD on relapse.

Up to 1 year

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Maro Ohanian, M.D. Anderson Cancer Center

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

19 settembre 2018

Completamento primario (Stimato)

31 dicembre 2027

Completamento dello studio (Stimato)

31 dicembre 2027

Date di iscrizione allo studio

Primo inviato

25 giugno 2018

Primo inviato che soddisfa i criteri di controllo qualità

5 luglio 2018

Primo Inserito (Effettivo)

18 luglio 2018

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

6 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 2017-0937
  • P30CA016672 (Sovvenzione/contratto NIH degli Stati Uniti)
  • 2017-0937 (Altro identificatore: M D Anderson Cancer Center)
  • NCI-2018-01108 (Identificatore di registro: CTRP (Clinical Trial Reporting Program))

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi